177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer.

MLA

Jie Zang, et al. “177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer.” Journal of Nuclear Medicine, vol. 61, no. 12, Dec. 2020, pp. 1–31. EBSCOhost, https://doi.org/10.2967/jnumed.120.242263.

APA

Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Jacobson, O., Xinrong Fan, Zhaohui Zhu, & Xiaoyuan Chen. (2020). 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61(12), 1–31. https://doi.org/10.2967/jnumed.120.242263

Chicago

Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, and Xiaoyuan Chen. 2020. “177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer.” Journal of Nuclear Medicine 61 (12): 1–31. doi:10.2967/jnumed.120.242263.